Goals of SCD treatment
Sickle cell disease is an inherited blood disorder that causes red blood cells to become rigid, sticky, and crescent-shaped. These abnormal cells can obstruct blood vessels, resulting in painful vaso-occlusive crises, chronic anemia, and damage to organs such as the spleen, lungs, and kidneys. Treatment focuses on reducing symptoms, preventing complications, improving quality of life, and, in suitable candidates, achieving a cure.
Hydroxyurea
Hydroxyurea remains a cornerstone of disease-modifying therapy for sickle cell disease. By boosting the production of fetal hemoglobin, it decreases the tendency of red blood cells to sickle. Clinical trials have demonstrated that hydroxyurea significantly reduces the frequency of pain crises, hospitalizations, and acute chest syndrome. It is commonly prescribed for both adults and children with recurrent symptoms.
Blood transfusions
Blood transfusions are used to treat severe anemia and to prevent life-threatening complications such as stroke. Chronic transfusion programs aim to keep the proportion of hemoglobin S below a target level, thereby reducing vaso-occlusive events. While effective, transfusions carry potential risks, including iron overload, alloimmunization, and transfusion-transmitted infections. Iron chelation therapy may be needed to manage iron accumulation.
Hematopoietic stem cell transplantation
Allogeneic hematopoietic stem cell transplantation, often referred to as bone marrow transplant, is the only established curative treatment for sickle cell disease. The procedure replaces a patient's diseased bone marrow with healthy stem cells from a compatible donor. Outcomes are best when a matched sibling donor is available. However, transplantation carries substantial risks, including graft-versus-host disease, infections, and transplant-related mortality. Eligibility is determined on a case-by-case basis.
Gene therapy and gene editing
Gene-based approaches represent a paradigm shift in sickle cell disease treatment. Gene therapy involves collecting a patient's own hematopoietic stem cells, modifying them in the laboratory to produce healthy red blood cells, and returning them to the patient after conditioning. Gene editing techniques, including CRISPR, are also being investigated to reactivate fetal hemoglobin expression. The first gene therapy for sickle cell disease received regulatory approval in 2023, offering a donor-independent curative option for eligible patients.
Pain management and supportive care
Supportive care is essential at every stage of the disease. Key measures include adequate hydration, folic acid supplementation, vaccination against encapsulated bacteria, and penicillin prophylaxis in children to prevent overwhelming infection. Acute pain crises require rapid assessment and analgesia, often with nonsteroidal anti-inflammatory drugs or opioids. Chronic pain may benefit from a multidisciplinary approach involving physical therapy, cognitive behavioral therapy, and non-opioid medications.
Emerging targeted therapies
Several newer agents have expanded the therapeutic arsenal. Crizanlizumab, a monoclonal antibody targeting P-selectin, reduces the frequency of vaso-occlusive crises. Voxelotor binds to hemoglobin and stabilizes its oxygenated state, reducing sickling and improving anemia. L-glutamine oral powder has been shown to lower pain crisis frequency and rates of hospitalization. These therapies offer additional options for patients with frequent complications.
Coordinated care and ongoing research
Optimal management of sickle cell disease requires a multidisciplinary team, including hematologists, pain specialists, nurses, and social workers. Newborn screening and comprehensive care programs have markedly improved survival. Research and clinical practice guidelines are supported by organizations such as the National Heart, Lung, and Blood Institute, the American Society of Hematology, and the World Health Organization. Patient advocacy and education are advanced by groups such as the Sickle Cell Disease Association of America.